Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License
22/04/2025 16:03
April 22 (Reuters) - JW (Cayman) Therapeutics Co Ltd 2126.HK: GRANTS JUNO THERAPEUTICS NON-EXCLUSIVE LICENSE UNDER JW SLVV MANUFACTURING PROCESS, OTHERS Further company coverage: 2126.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on JW (Cayman) Therapeutics Co
See all newsChina pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License